Executive summary

Treatment and acute toxicity data of 17 chordoma and 3 chondrosarcoma patients treated with IMPT were retrospectively evaluated in this study. This study found that treatment plan adaptation was needed in 5 out of 22 (22.7%) plans due to either reduced tumor coverage or increased dose to the OAR. The conclusion is that robust IMPT for chordoma and chondrosarcoma of the mobile spine is feasible and plan adaptations due to anatomical changes were required in approximately 23 percent of treatment courses.

Top cancer treatments